Joaquı́n Mateo
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
2015/10/28 by Joaquı́n Mateo, Joaquin Mateo, Suzanne Carreira +57 · 14 citations
Medicine · #Prostate Cancer Treatment and Research #PARP inhibition in cancer therapy #Prostate Cancer Diagnosis and Treatment
- Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
2020/08/24 by F. Mosele, Fernanda Mosele, Jordi Remón +39 · 4 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Cancer Genomics and Diagnostics #Genetic factors in colorectal cancer #Pancreatic and Hepatic Oncology Research
- Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
2024/05/27 by M.F. Mosele, C. Benedikt Westphalen, C.B. Westphalen +38 · 9 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Cancer Genomics and Diagnostics #Lung Cancer Treatments and Mutations #Colorectal Cancer Treatments and Studies
- Elucidating acquired PARP inhibitor resistance in advanced prostate cancer
2024/11/21 by George Seed, Nick Beije, Wei Yuan +33 · 2 voices · 1 citation
Medicine · #PARP inhibition in cancer therapy #Prostate Cancer Diagnosis and Treatment #Prostate Cancer Treatment and Research
- Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer
2025/10/07 by Nofar Gumpert, Shira Sagie, Claudia Arnedo-Pac +33 · 1 voice · 2 citations
Medicine · Immunology and Microbiology · #Cancer Immunotherapy and Biomarkers #Prostate Cancer Treatment and Research #Immunotherapy and Immune Responses